Dose adjustment of antidiabetic medications in chronic kidney disease

Purpose: The purpose of this study is to identify whether Internal Medicine house-staff (IMHS) have awareness and knowledge about the correct dosage of antidiabetic medications for patients with chronic kidney disease (CKD), as dosing errors result in adverse patient outcomes for those with diabetes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matthew Salvatore Snyder, Joshua Fogel, Svetlana Pyatigorskaya, Sofia Rubinstein
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Materias:	adult-onset diabetes mellitus chronic kidney insufficiency internal medicine medication error residency and internship Medicine R
Acceso en línea:	https://doaj.org/article/e6b89237c534419f9e7c9e98f45bc758
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6b89237c534419f9e7c9e98f45bc758
record_format	dspace
spelling	oai:doaj.org-article:e6b89237c534419f9e7c9e98f45bc7582021-12-02T17:07:08ZDose adjustment of antidiabetic medications in chronic kidney disease2231-07702249-446410.4103/ajm.ajm_110_20https://doaj.org/article/e6b89237c534419f9e7c9e98f45bc7582021-01-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.4103/ajm.ajm_110_20https://doaj.org/toc/2231-0770https://doaj.org/toc/2249-4464Purpose: The purpose of this study is to identify whether Internal Medicine house-staff (IMHS) have awareness and knowledge about the correct dosage of antidiabetic medications for patients with chronic kidney disease (CKD), as dosing errors result in adverse patient outcomes for those with diabetes mellitus (DM) and CKD. Methods: There were 353 IMHS surveyed to evaluate incorrect level of awareness of medication dose adjustment in patients with CKD (ILA) and incorrect level of knowledge of glomerular filtration rate level for medication adjustment (ILK-GFR) for Glipizide, Pioglitazone, and Sitagliptin. Results: Lack of awareness and knowledge was high, with the highest for Pioglitazone at 72.8%. For ILA, the percentages were: Pioglitazone: 72.8%, Glipizide: 43.9%, and Sitagliptin: 42.8%. For ILK-GFR, the percentages were: Pioglitazone: 72.8%, Glipizide: 68.3%, and Sitagliptin: 65.4%. Conclusions: IMHS have poor awareness and knowledge for antidiabetic medication dose adjustment in patients with DM and CKD. Both Electronic Medical Rerecord best practice advisory and physician–pharmacist collaborative drug therapy management can enhance safe drug prescribing in patients with CKD. In addition, IMHS’s practice for antidiabetic medication dose adjustment was better with Nephrology exposure. A formal didactic educational training during medical school and residency for antidiabetic medication dose adjustment in patients with DM and CKD is highly encouraged to prevent medication dosing errors and to more effectively and safely allow IMHS to manage complex treatment regimens.Matthew Salvatore SnyderJoshua FogelSvetlana PyatigorskayaSofia RubinsteinThieme Medical and Scientific Publishers Pvt. Ltd.articleadult-onset diabetes mellituschronic kidney insufficiencyinternal medicinemedication errorresidency and internshipMedicineRENAvicenna Journal of Medicine, Vol 11, Iss 01, Pp 33-39 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adult-onset diabetes mellitus chronic kidney insufficiency internal medicine medication error residency and internship Medicine R
spellingShingle	adult-onset diabetes mellitus chronic kidney insufficiency internal medicine medication error residency and internship Medicine R Matthew Salvatore Snyder Joshua Fogel Svetlana Pyatigorskaya Sofia Rubinstein Dose adjustment of antidiabetic medications in chronic kidney disease
description	Purpose: The purpose of this study is to identify whether Internal Medicine house-staff (IMHS) have awareness and knowledge about the correct dosage of antidiabetic medications for patients with chronic kidney disease (CKD), as dosing errors result in adverse patient outcomes for those with diabetes mellitus (DM) and CKD. Methods: There were 353 IMHS surveyed to evaluate incorrect level of awareness of medication dose adjustment in patients with CKD (ILA) and incorrect level of knowledge of glomerular filtration rate level for medication adjustment (ILK-GFR) for Glipizide, Pioglitazone, and Sitagliptin. Results: Lack of awareness and knowledge was high, with the highest for Pioglitazone at 72.8%. For ILA, the percentages were: Pioglitazone: 72.8%, Glipizide: 43.9%, and Sitagliptin: 42.8%. For ILK-GFR, the percentages were: Pioglitazone: 72.8%, Glipizide: 68.3%, and Sitagliptin: 65.4%. Conclusions: IMHS have poor awareness and knowledge for antidiabetic medication dose adjustment in patients with DM and CKD. Both Electronic Medical Rerecord best practice advisory and physician–pharmacist collaborative drug therapy management can enhance safe drug prescribing in patients with CKD. In addition, IMHS’s practice for antidiabetic medication dose adjustment was better with Nephrology exposure. A formal didactic educational training during medical school and residency for antidiabetic medication dose adjustment in patients with DM and CKD is highly encouraged to prevent medication dosing errors and to more effectively and safely allow IMHS to manage complex treatment regimens.
format	article
author	Matthew Salvatore Snyder Joshua Fogel Svetlana Pyatigorskaya Sofia Rubinstein
author_facet	Matthew Salvatore Snyder Joshua Fogel Svetlana Pyatigorskaya Sofia Rubinstein
author_sort	Matthew Salvatore Snyder
title	Dose adjustment of antidiabetic medications in chronic kidney disease
title_short	Dose adjustment of antidiabetic medications in chronic kidney disease
title_full	Dose adjustment of antidiabetic medications in chronic kidney disease
title_fullStr	Dose adjustment of antidiabetic medications in chronic kidney disease
title_full_unstemmed	Dose adjustment of antidiabetic medications in chronic kidney disease
title_sort	dose adjustment of antidiabetic medications in chronic kidney disease
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2021
url	https://doaj.org/article/e6b89237c534419f9e7c9e98f45bc758
work_keys_str_mv	AT matthewsalvatoresnyder doseadjustmentofantidiabeticmedicationsinchronickidneydisease AT joshuafogel doseadjustmentofantidiabeticmedicationsinchronickidneydisease AT svetlanapyatigorskaya doseadjustmentofantidiabeticmedicationsinchronickidneydisease AT sofiarubinstein doseadjustmentofantidiabeticmedicationsinchronickidneydisease
_version_	1718381589707096064

Dose adjustment of antidiabetic medications in chronic kidney disease

Ejemplares similares